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Thrombopoietin (TPO) receptor agonists represent a new approach for the treatment of thrombocytopenia, which may develop
as a consequence of immune thrombocytopenia, chemotherapy treatment, chronic hepatitis C infection, or myelodysplastic
syndromes. There are concerns that use of certain growth factors can hasten disease progression in some types of hematologic
malignanciesand solid tumors.In this study, expression of MPL (TPO-R) mRNA was examined in tumor cell lines, patient tumor
samples (renal cell carcinoma, prostatic carcinoma, soft tissue and bony/cartilage sarcoma, colon cancer, and lymphoma), and
normal tissues using microarray analysis and qRT-PCR. MPL mRNA is expressed at very low or undetectable levels compared
with erythropoietin receptor (EPOR), human epidermal growth factor (ERBB2; HER2), and insulin-like growth factor-1 receptor
(IGF1R) in these patient samples. These data suggest TPO-R agonists will likely preferentially stimulate proliferation and
diﬀerentiation of cells of megakaryocytic lineage, potentially demonstrating their utility for correcting thrombocytopenia in
clinical settings.
1.Introduction
Thrombopoietin (TPO) is the key cytokine involved in
the regulation of thrombopoiesis. Its activities are twofold:
TPO stimulates both megakaryocyte colony formation and
enhances megakaryocyte maturation. Megakaryocytes and
their precursors possess the thrombopoietin receptor (TPO-
R; MPL) on their surfaces. TPO is constitutively expressed,
but the level of circulating TPO is directly related to platelet
mass [1–5]. The JAK-STAT signal transduction pathway is
activated upon binding of TPO to its receptor, resulting in
changes in gene expression that promote megakaryocytic
diﬀerentiation,increase megakaryocyte ploidy,andstimulate
the release of platelets into the peripheral circulation.
Thrombocytopenia, deﬁned as a platelet count less than
150,000/μL, represents an important clinical issue because
it can increase the risk for bleeding. Spontaneous bleeding
can occur when platelet counts drop below 20,000/μL[ 6]. It
developsas a result ofan imbalance between plateletproduc-
tion and platelet consumption. Thrombocytopenia develops
commonly in patients with a variety of conditions including
HIV, chronic hepatitis C infection, portal hypertension,
systemic lupus erythematosus, myelodysplastic syndromes,
and cancer [7–11]. Thrombocytopenia can also result from
myelosuppressive chemotherapy, although bleeding episodes
are infrequent overall. Thrombocytopenia can result in dose
delays and dose reductions of chemotherapy that could
negatively impact disease control [11]. However, bleeding2 Journal of Oncology
is associated with poor performance status, multiple comor-
bidities, bone marrow metastases, and low baseline platelet
counts, and, when it occurs, bleeding predicts poor clini-
cal outcomes [11]. Although development of recombinant
TPO was discontinued because of neutralizing antibody
formation,2TPO-Ragonists,eltrombopagandromiplostim,
have been approved for the treatment of chronic immune
thrombocytopenicpurpura (ITP) intheUnitedStates.These
TPO-R agonists stimulate TPO-dependent cell lines via
JAK-STAT signaling and demonstrate increased platelets in
humans [6, 12–15].
Other growth factors have the potential to stimu-
late growth of tumors. A recent review article described
the use of erythropoiesis-stimulating agents to increase
hemoglobin levels in patients with cancer; numerous studies
were identiﬁed in which use of these drugs increased the
risk of treatment-associated death, perhaps through tumor
progression [16, 17]. Erythropoietin receptor messenger
ribonucleic acid (mRNA) and/or protein has been identiﬁed
in a wide range of cancers, leading to the speculation
that tumor progression may be a consequence of activa-
tion of endogenous erythropoietin receptors by exogenous
erythropoiesis-stimulating agents, thereby promoting tumor
cell proliferation and angiogenesis and inhibiting apoptosis.
Acute myelogenous leukemia (AML) blast cells express MPL
mRNA and protein [18]. TPO stimulated blast colony
formation in samples from approximately 50% of patients
with AML in one study [19], and enhanced proliferation of a
megakaryocytic leukemic cell line [20]. Results from other
investigators conﬁrmed this and demonstrated that TPO
induced cell cycle activation and could protect AML blasts
from programmed cell death [21]. Eltrombopag does not
appear to stimulate proliferation of AML/myelodysplastic
syndromes (MDSs) patient blood and marrow samples
or nonmegakaryocytic leukemia and lymphoma cell lines
[22–24]. In fact, there is a decrease in proliferation at
physiologically achievable concentrations of eltrombopag.
Although the intensity of signaling induced by eltrombopag
is lower than that induced by TPO, a mechanism for this
diﬀerential eﬀect has not been identiﬁed [14, 22, 23].
There is little quantitative information available on
the expression of TPO-R on solid tumors. In a recent
examination of breast, nonsmall cell lung cancer (NSCLC),
and ovarian tumor samples, very little, or more often, no
MPL expression was detectable on these patient samples
[25]. To further our knowledge of MPL mRNA expression,
quantitative reverse transcription-polymerase chain reaction
(qRT-PCR) and microarray analysis were performed on
tumor cell lines and in tumor samples from renal cell
carcinomas, prostate cancers, lymphomas, colon cancers,
and sarcomas.
2.Methods
2.1. Tumor Cell Lines. Three hundred and ﬁfty-ﬁve cell lines
of various tissue types were obtained from the American
Type Culture Collection (Rockville, MD, USA), the German
Collection of Microorganisms and Cell Cultures (Braun-
schweig, Germany), the National Cancer Institute (Bethesda,
MD, USA), and the European Collection of Cell Cultures
(Salisbury, UK).Allcellswere in logphase growthatthe time
ofcollection.Thecompletelistoftumorcelllinesusedinthis
study is provided in the Supplementary Material available
online at doi: 10.1155/2010/135354.
2.2. Patient Tissue Samples. Colon (5 normal, 42 tumor),
prostate (7 normal, 30 tumor, 11 benign hypertrophy), and
lymphoma (3 normal spleen, 3 normal lymph nodes, 42
lymphoma) cDNA samples were obtained from Cytomyx
LLC (Lexington, MA, USA). Archival tissue samples were
also obtained from 105 patients with locally advanced or
metastatic renal cell carcinoma (RCC) who failed, or who
were unable to tolerate, ﬁrst-line cytokine-based therapy.
These patients were selected for epidermal growth factor
receptor (EGFR) and/or ERBB2 positive (1+, 2+, or 3+)
tumors. Archival tissue samples were obtained from an addi-
tional 46 patients who had metastatic or locally recurrent
RCC of clear cell histology. These individuals either had no
prior systemic therapy or had failed only 1 prior cytokine-
based or bevacizumab-based therapy.
Additional archival tissue samples from 22 patients
with soft tissue sarcomas (14 leiomyosarcomas, 8 malignant
ﬁbrous histiocytomas) and 12 bony/cartilage sarcomas (3
chondroblastomas, 7 osteosarcomas, 1 chordoma, 1 enchon-
droma) were obtained from the University of Pennsylvania
(Philadelphia, PA, USA).
2.3. Microarray Analysis. Clinical tissue samples were all
formalin ﬁxed and paraﬃn embedded. RNA is often frag-
mented in these samples. To ensure the quality of RNA
extraction, tumor tissues were microdissected using laser
capture microdissection. RNA was rapidly extracted; 100
base pair (bp), 300bp, and 400bp segments of the β-actin
gene were tested using qRT-PCR. Samples with less than 32
cycle threshold (Ct) at the 300bp level and less than 34Ct at
the 400bp level were included in the microarray analysis.
Microarray analysis of all RCC samples was performed
at Response Genetics, Inc. (Los Angeles, CA, USA) using
the Aﬀymetrix HG-U133 Plus2 chip. Microarray analysis
was performed on the sarcoma tissue samples, using the
Aﬀymetrix HG-U133chip, atthe University of Pennsylvania.
RNA microarray gene signal intensity was normalized using
robust microarray average (RMA) analysis as described by
Irizarry [26].
2.4. qRT-PCR Analysis. Primers and probes were customly
made byIntegratedDNATechnologies (Coralville,IA,USA).
S e q u e n c e sf o rt h ep r i m e r sa n dp r o b e su s e di nt h i ss t u d ya r e
listed in the Supplementary material.
Cells from each cell line were lysed in Trizol reagent
(Invitrogen). After phase separation with chloroform, total
RNA was extracted using the RNeasy Mini Kit (Qiagen, Ger-
mantown, MD, USA) following the manufacturer’s instruc-
tions. Genomic DNA contamination was removed using
DNase I (Ambion, Austin, TX, USA). RNA samples wereJournal of Oncology 3
considered to be free of genomic DNA if no ampliﬁcation
was observedinastandard TaqMan assay using10ngofRNA
and ACTB primer/probe oligonucleotides. The RNA was
quantiﬁed using a Nanodrop analyzer and was subsequently
converted to cDNA by reverse transcription utilizing the
High Capacity cDNA Archive Kit (Applied Biosystems Inc.,
Foster City, CA, USA).
qRT-PCR was also performed on the cDNA from both
the normal and tumor tissue samples and from the cell
lines to assess the levels of MPL, erythropoietin receptor
(EPOR), human epidermal growth factor (ERBB2; HER2),
and insulin-like growth factor-1 receptor (IGF1R). Data
were normalized to a set of housekeeping genes used as
internal standards including GADPH, PPIA (cyclophilin-A),
and ACTB (β-actin). The equivalent of 10ng mRNA per
well was arrayed into 384-well plates using a Biomek FX
robot(BeckmanCoulter, Inc.,Fullerton,CA,USA)and qRT-
PCR was carried out using a 7900HT Sequence Detector
System (Applied Biosystems Inc.) in a 5μL reaction volume.
TaqMan Universal PCR Master Mix 2X (Applied Biosystems
Inc.) and universal PCR conditions recommended by the
manufacturer were followed.
Ct values were analyzed using in-house analysis soft-
ware in which values were normalized to the internal
housekeeping genes in the reaction. Only samples with
suﬃcienthousekeepinggeneexpression (Ct < 32)were used.
Abundance was calculated using the formula: abundance =
10e((40 − Ct)/3.35). To normalize the data, samples were
scaled relative to each other using the geometric mean
of the set of valid housekeeping gene datapoints for that
sample. Each datapoint was then expressed as the ratio of the
housekeeping gene abundance in the sample to the average
abundance of that housekeeping gene in all samples and
marked invalid if it had statistically inconsistent behavior
with the other housekeeping genes in those samples with
similar tissue types.
3.Results
Inmostofthe355tumorcelllinesanalyzed, MPLmRNAwas
e x p r e s s e do n l ya tv e r yl o wl e v e l s( Figure 1). Only 3 cell lines
demonstrated expression of MPL mRNA in excess of 9500
normalized abundance, as illustrated in Figure 1.T h e s ew e r e
the erythroleukemia cell lines HEL 92.1.7 and KG-1 and the
lung tumor cell line NCI-H510.
Table 1 summarizes normalized mRNA abundance for
MPL, EPOR, ERBB2,a n dIGF1R in all the cell lines
studied.MPLexpression wasminimal. Themeannormalized
abundance for MPL mRNA was 1447 and the mode was 621.
EPOR mRNA, in contrast, was expressed at low to moderate
levels (mean 12,587; mode 7811) and ERBB2 mRNA expres-
sion was markedly greater (mean 280,190; mode 40,828) as
was IGF1R mRNA expression mean 78,977; mode 56,625).
The highest expression of ERBB2 was observed in breast
tumor cell lines, as expected. ERBB2 and IGF1R mRNA
demonstrated particularly higher expression than MPL or
EPOR i nl u n g ,b r a i n ,b r e a s t ,a n db l a d d e rc e l ll i n e s ,a ss h o w n
in Figure 1.
Table 1: Normalized Abundance of MPL, EPOR, ERBB2,a n d
IGF1R mRNA Across 355 Tumor Cell Line Types.
Cycle Threshold Values
Mode Mean SD Minimum Maximum
MPL 621 1447 463 1 172,402
EPOR 7811 12,587 1055 1 311,201
ERBB2 40,828 280,190 63,578 197 12,632,200
IGF1R 56,625 78,977 3914 1 535,859
EPOR: erythropoietin receptor; ERBB2: human epidermal growth factor;
IGF1R: insulin growth factor-1 receptor; MPL: thrombopoietin receptor;
SD: standard deviation.
Cycle threshold values were calculated and samplesnormalized as described
in the Materials and Methods section.
Table 2: Number (%) of Primary Tumor Samples With Detectable
MPL mRNA Expression Determined by Microarray Analysis.
n (%) RCC
n = 151
Soft Tissue Sarcomas
n = 22
Bony/Cartilage
Sarcomas
n = 12
MPL 0 7 (32) 4 (33)
EPOR 132 (87) 6 (27) 4 (33)
ERBB2 122 (81) 21 (95) 9 (75)
IGF1R 81 (54) ND ND
EPOR: erythropoietin receptor; ERBB2: human epidermal growth factor;
IGF1R: insulin growth factor-1 receptor; MPL: thrombopoietin receptor;
ND: not determined; RCC: renal cell carcinoma; RMA: robust microarray
averages. Detectable expression is determined by a RMA ≥ 50.
Microarray data analysis of MPL mRNA expression
was performed on primary tumor samples from RCC and
soft tissue and bony/cartilage sarcomas. None of the 151
RCC tumors expressed MPL mRNA at detectable levels
(RMA ≥ 50) (Figure 2, Table 2). However, 132 (87%)
showed detectable levels of EPOR mRNA, and 122 (81%)
demonstrated ERBB2 mRNA expression. Fewer RCC tumor
samples (81; 54%) expressed detectable IGF1R mRNA.
EPOR, ERBB2,a n dIGF1R mRNA levels were overall lower
in these RCC samples than those observed in the breast and
NSCLC tumors previously described [25].
Seven of 22 (32%) soft tissue sarcomas and 4/12
bony/cartilage sarcomas (33%) expressed MPL mRNA at
detectable levels (Figure 2(b), Table 2). Similarly, 6/22 (27%)
soft tissue and 4/12 (33%) bony/cartilage samples showed
detectable levels of EPOR. The majority of samples (21/22
(95%) and 9/12 (75%), respectively) expressed detectable
ERBB2 mRNA.
Microarrayanalysisisbestusedtodescriberelativediﬀer-
ences in mRNA levels. qRT-PCR analysis was performed on
additional samples to more quantitatively determine mRNA
expression in normal tissues and tumor samples. The qRT-
PCR data were normalized to a set of 3 housekeeping genes.
Among prostate samples, no normal or benign pro-
static hypertrophy samples expressed detectableMPLmRNA
whereas 1 tumor (3%) expressed MPL (Table 3, Figure 3).
All samples expressed detectable levels of EPOR and ERBB2.4 Journal of Oncology
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Figure 1: Quantitative reverse transcription-polymerase chain reaction measurement of MPL, EPOR, ERBB2,a n dIGF1R mRNA in various
tumor cell lines. Data were normalized to a set of housekeeping genes (GAPDH, cyclophilin, and β-actin). The normalized abundance of
mRNA (y-axis) is scaled to 175,000 for all samples. Cycle threshold (Ct) values were calculated using the following equation: Abundance =
10e((40 − Ct)/3.35). Samples were scaled relative to each other using the geometric mean of the set of valid housekeeping gene datapoints
for that sample.
IGF1R mRNA expression was also common with 4/7 (57%)
normal prostate samples, 25/30 (83%) prostate tumors,
and 7/11 (64%) benign prostatic hypertrophy samples
expressing detectable levels.
None of the 6 normal lymph node and spleen samples
or 42 lymphoma samples expressed detectable levels of MPL,
ERBB2,o rIGF1R mRNA (Table 3, Figure 3). In contrast,
3/6 (50%) normal lymph node and spleen samples and
10/42 (24%) lymphoma samples expressed detectable EPOR
mRNA.
None of the 5 normal colon samples or 42 colon tumors
expressed detectable MPL mRNA (Table 3, Figure 3). IGF1R
mRNA expression was detectable in 1 (20%) normal and 5
(12%) adenocarcinoma of the colon samples. However, all
of the normal colon samples and 27 (64%) colon tumors
expressed detectable EPOR mRNA and all samples expressed
detectable ERBB2.
The stage of disease was available for the samples of
lymphoma and colon and prostate tumors, however, due
to the lack of detectable expression of MPL mRNA in
these tumor types, no interpretation could be made on the
relationships between expression levels and stage of disease.
4.Discussion
Thrombocytopenia can be a consequence of diminished
platelet production in the bone marrow, or increased
platelet consumption in the spleen, liver, or circulation.
Currently, platelet transfusions are used for the treatment
of acute thrombocytopenia due to a variety of etiologiesJournal of Oncology 5
Table 3: Number (%) of Primary Tumor Samples With Detectable mRNA Expression Determined by qRT-PCR.
n (%) Prostate Normal
n = 7
Prostate Tumor
n = 30
Benign Prostatic
Hypertrophy
n = 11
Normal Lymph
Node and Spleen
n = 6
Lymphoma
n = 42
Colon Normal
n = 5
Colon Tumor
n = 42
MPL 0 1 ( 3 ) 00000
EPOR 7 (100) 30 (100) 11 (100) 3 (50) 10 (24) 5 (100) 27 (64)
ERBB2 7 (100) 30 (100) 11 (100) 0 0 5 (100) 42 (100)
IGF1R 4 (57) 25 (83) 7 (64) 0 0 1 (20) 5 (12)
EPOR: erythropoietinreceptor; ERBB2: human epidermal growth factor; IGF1R: insulin growth factor-1 receptor; MPL: thrombopoietin receptor; qRT-PCR:
quantitative reverse transcription-polymerasechain reaction.
Detectable expression is determined by a normalized abundance ≥50.
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Figure 2: Measurement of MPL, EPOR, ERBB2,a n dIGF1RmRNA inrenal cell carcinomaand softtissue andbony/cartilage sarcomatumor
samples using microarray analysis. Robust microarray average (RMA) was used for assay normalization. The levels of gene expression of
MPL, EPOR, ERBB2,a n dIGF1R mRNA were reported as RMA intensity values.
[27]. However, signiﬁcant limitations exist to the use of
platelet transfusions. Many patients become refractory to
transfusion. Limited availability and cost concerns further
impact the utility of platelet transfusion as an optimal
treatment for thrombocytopenia. Despite donor testing and
pathogeninactivation systems, infections with HIV, hepatitis
B or C viruses, cytomegalovirus, or bacteria are possible.
Alloimmunization and febrile transfusion reactions are 2
of the immunologically mediated adverse events that can
follow platelet transfusion. And, transfusion-related acute
lung injury is a potentially fatal immunologic consequence
of transfusions of plasma containing blood products. There-
fore, alternative treatments with fewer inherent challenges
are sought. TPO-R agonists represent a class of such agents.
Eltrombopag is approved for use in patients with chronic
ITP and is currently in clinical trials for thrombocytopenia
in patients with MDS/secondary AML and for thrombocy-
topenia due to chemotherapy in patients with solid tumors.
The expression of EPOR, ERBB2, and IGF1R genes in
tumorshas beenwell studiedand is widelyreported, thusthe
expression of these genes was used as a comparator for MPL
[28–33].6 Journal of Oncology
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Figure 3: Quantitative reverse transcription-polymerase chain reaction measurement of MPL, EPOR, ERBB2,a n dIGF1R mRNA in various
normaltissuesamplesandtumorsamples.Datawere normalizedtoasetofhousekeeping genes(GAPDH,PPIA,andACTB).Cyclethreshold
(Ct) values were calculated usingthe followingequation: Abundance = 10e((40−Ct)/3.35).Samples were scaled relative to each other using
the geometric mean of the set of valid housekeeping gene datapoints for that sample.
It should be understood that expression of these genes
does not always mean that the protein is detected on
the cell surface. Nor does expression of a receptor pro-
tein necessarily reﬂect signaling or proliferation can occur
[34, 35]. The expression of TPO-R protein by Western
blotting of several lung tumor cell lines, including NCI-
H510, which was one of the 3 cell lines that demonstrated
high mRNA expression in this study, showed no protein
expression in any of these lines [25]. Although, there are
reports of AML cells-expressing MPL, 2 recent studies found
no proliferation of cells in blood and marrow samples
from patients with AML or MDS/secondary AML [22],
or in leukemia and lymphoma cell lines in response to
eltrombopag [23]; in fact, there is a decrease in proliferation
at physiologically achievable concentrations of eltrombopag
[22, 23].
Activity of TPO-R agonists depends on the expression
of TPO-R in the tissue of interest. Likewise, expression
of TPO-R on cells other than megakaryocytes is of great
interest; activation of growth factor receptors such as TPO-
R could theoretically enhance proliferation in such tissue.
The goal of this study, therefore, was to expand on the
MPL mRNA expression data by microarray and qRT-PCR
previously described for breast, lung, and ovarian tumors
[25]intoothertumortypesandtumorcelllines.MPLmRNA
was consistently expressed at low or undetectable levels in
the 355 tumor cell lines studied. MPL mRNA was expressed
at detectable levels in 3 cell lines, the erythroleukemia lines
HEL92.1.7 and KG-1, and the NCI-H510 lung tumor cell
line. The HEL92.1.7 line serves as a positive control cell
line in this study, as it expresses some MPL mRNA and
gives a very slight, but statistically signiﬁcant, proliferativeJournal of Oncology 7
response to eltrombopag [23]. A comparison of the MPL
mRNA expression in this line to several other leukemia
cell lines, including the NOMO-1 F36-P and ML-2 cell
lines, also represented in Figure 1, was previously reported
[23]. In comparison, EPOR mRNA was expressed in low-
to-moderate levels and ERBB2 and IGF1R mRNA were
expressedathigherlevels.Asexpected,breasttumorcelllines
typicallyexpressedmuchhigherlevelsofERBB2mRNA.This
tumor cell line data reinforced data in samples of breast and
lung tumor from patients [25].
Microarray data of tumor samples revealed similar
results. MPL mRNA levels were low or below the limits
o fd e t e c t i o ni na l lt u m o rs a m p l e se x a m i n e d .T h em a j o r i t y
of tumor samples expressed mRNA for EPOR, ERBB2,a n d
IGF1R at varying levels. One caveat to this type of data is
that the expression on normal tissues of each type are not
m e a s u r e d .T ot h i se n d ,q R T - P C Ro fb o t hn o r m a lt i s s u e s
and tumor samples permitted a direct comparison of mRNA
levels.MPLmRNAexpressionwaslowinbothnormaltissues
and in prostate, colon, and lymphoma tumor samples, and
MPLmRNA was not increased in any tumor tissue relative to
normal tissue.
5.Conclusions
Because the levels of MPL mRNA are low or undetectable
in RCC, sarcoma, prostate, and colon tumors as well as
lymphoma samples, it is unlikely that TPO-R agonists
can induce proliferation of these types of tumor cells.
Rather, TPO-R agonists will likely preferentially stimulate
proliferation and diﬀerentiation of megakaryocytic cells to
produce platelets and relieve thrombocytopenia. These data
provide additional support for continued study of TPO-R
agonists for the treatment of oncology-related thrombocy-
topenia and demonstrate their potential utility for correcting
thrombocytopenia in clinical settings.
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